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Review 
Bacteriological Activity of Trovafloxacin, 
a New Quinolone, against Respiratory Tract Pathogens 
J.-C. Pech6re, T. D. Gootz 
Abstract The use of established fluoroquinolones, such as ciprofloxacin and oflox- 
acin, as empirical therapy for the treatment of moderate-to-severe respiratory tract 
infections is limited by their poor activity against gram-positive and atypical 
pathogens. Data from in vitro susceptibility studies and in vivo animal protection 
models suggest hat the new fluoroquinolone, trovafloxacin, compared with cipro- 
floxacin and ofloxacin offers equivalent activity against gram-negative pathogens 
and improved activity against gram-positive pathogens. In particular, susceptibility 
data indicate that trovafloxacin is at least 16-fold more potent han either ciproflox- 
acin or ofloxacin against penicillin-susceptible and penicillin-resistant s rains of 
Streptococcus pneurnoniae. Other susceptible pathogens include Streptococcus 
pyogenes, vancomycin-susceptible Enterococcus faecalis and the atypical respiratory 
pathogens Legionella pneurnophila, Mycoplasma pneumoniae and Chlamydia pneu- 
moniae. In vivo studies involving models of protection against acute systemic infec- 
tion and pneumococcal pneumonia in mice, and Legionnaires' disease in guinea pigs, 
indicate that the antibacterial spectrum observed for trovafloxacin vitro extends to 
the in vivo setting. Together, these findings uggest that trovafloxacin may offer clin- 
ical efficacy against respiratory pathogens uperior to that of ciprofloxacin and of 
ofloxacin, and may find a useful role as empiric therapy in both the community and 
hospital setting. 
Introduction 
High incidences of penicillin resistance [1], escalating 
/3-1actamase production and poor activity against 
atypical pathogens are increasingly limiting the use of 
/3-1actam antibiotics for the empiric treatment of respi- 
ratory tract infections. Macrolides have been used as 
alternative agents, but there is growing concern about 
the emergence of resistance to this class of antibiotics, 
particularly with Streptococcus pneumoniae. Clinicians 
are now searching for other antibiotics that can provide 
cost-effective, ideally single-agent, empiric therapy for 
moderate-to-severe community- and hospital-acquired 
respiratory infections. 
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The established fluoroquinolone antibiotics exhibit 
excellent activity against a broad spectrum of gram- 
negative pathogens, resulting in their use as mono- 
therapy for acute exacerbations of chronic bronchitis 
and as part of a combination therapy for hospital- 
acquired pneumonia. By contrast, the activity of estab- 
lished fluoroquinolones is only moderate against Strep- 
tococcus pneumoniae and Mycoplasrna pneumoniae; 
thus their use as first-line therapy for community- 
acquired pneumonia is not widely accepted. 
There is a need, therefore, for new fluoroquinolones 
that offer improved activity against gram-positive and 
atypical respiratory pathogens. Trovafloxacin is a novel 
fluoronaphthyridone with a similar structure to existing 
fluoroquinolones. This article reviews the preclinical 
evaluation of trovafloxacin against respiratory patho- 




Most currently available quinolone antibacterial gents 
possess the same core structure (Figure la). Experience 
gained during the development of the quinolones has 
confirmed the importance of the nitrogen at N-l, the 
ketone at C-4, the carboxylic group at C-3 and the fluo- 
ride at C-6 for potent antimicrobial ctivity. Most of the 
variation in structure and activity within this family of 
compounds is derived from substitutions at positions 
N-1 and C-7 [2]. Trovafloxacin (CP-99,219), a fluoro- 
naphthyridone, while retaining the quinolone core struc- 
ture, has a combination of structural moieties not found 
in other fluoroquinolones: a 3-azabicyclo[3.1.0]hexyl 
substitution at C-7 and a 2,4-difluorophenyl group at 
the N-1 position (Figure lb). The nitrogen atom at the 
C-8 position, which renders trovafloxacin a naphthyri- 
done, appears to be associated with a long elimination 
half-life [3]. 
Mode of Action of Trovafloxacin 
Trovafloxacin, in common with the established fluoro- 
quinolones, elicits its bactericidal action by interacting 
with and inhibiting the action of bacterial DNA gyrase, 
i.e., topoisomerase II [4, 5]. A second topoisomerase, 
topoisomerase IV, appears to be a secondary target for 
fluoroquinolones in Escherichia coli [6] and Neisseria 
gonorrhoeae [7], and the primary target for ciproflox- 
acin and trovafloxacin Staphylococcus aureus [8], and 
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Figure 1 Chemical structures of(a) quinolone antibiotics and (b) 
tra,;a flt~-z ~ eln 
Streptococcus pneumoniae [9]. The agent does not 
inhibit eukaryotic topoisomerase II and, therefore, is 
not cytotoxic towards human cells [10]. 
Mechanisms of Resistance to Fluoroquinolones 
The dominant factor in the emergence of resistance to 
fluoroquinolones appears to be mutation of DNA 
gyrase in gram-negative and of topoisomerase IV in 
gram-positive organisms [3]. An additional mechanism 
of resistance includes the presence of efflux trans- 
porters [11-13], which actively export ftuoroquinolones 
from within the bacteria. The role of porins and outer 
membrane permeability is more questionable. 
Studies in Streptococcus pneumoniae [9], Staphylo- 
coccus aureus [14] and Pseudomonas aeruginosa [15] 
have indicated that trovafloxacin has a reduced poten- 
tial to select fluoroquinolone r sistance compared with 
other agents, such as ciprofloxacin. 
Antimicrobial Activity in Vitro 
A large number of microbiological studies have evalu- 
ated the in vitro susceptibilities of gram-negative, gram- 
positive and atypical respiratory pathogens to trova- 
floxacin, ciprofloxacin and ofloxacin. Typically, these 
studies determined, using National Committee for Clin- 
ical Laboratory Standards recommended procedures 
[16], the minimal concentrations of one or more of the 
antibiotics that inhibit the growth of 90% of the bac- 
terial isolates tudied (MIC90), enabling median MICgo 
values to be calculated. 
Gram-Positive Respiratory Pathogens. The in vitro 
data indicate that trovafloxacin offers inhibitory 
activity that is markedly superior to that of either cipro- 
floxacin or ofloxacin against most gram-positive 
pathogens (Table 1). For both penicillin-susceptible 
and -resistant (MIC _>0.5 rag/l) Streptococcus pneu- 
moniae strains the median MtC90 is 0:12 rag/l, with a 
maximum recorded MIC of 0.5 rag/1 and is at least 16- 
fold more potent han either ciprofloxacin or ofloxacin. 
Maximum MICs of 8rag/1 were recorded for both 
ciprofloxacin and ofloxacin. Methiciliin-susceptible 
Staphylococcus aureus is highly susceptible to trova- 
floxacin (median MIC9o 0.06 mg/1) compared with 
ciprofloxacin (0.75 mE/l) and ofloxacin (0.5 mE/l). Like- 
wise, trovafloxacin is at least 12- and eightfo!d more 
potent than ciprofloxacin and ofloxacin, respectively, 
against methicillin-resistant Staphylococcus aureus, and 
at least eightfold more potent against ciprofloxacin- 
resistant isolates; the clinical significance of these 
differences remains to be determined. Superior activity 
of trovafloxacin against Streptococcus pyogenes has also 
been detected. Some isolates of enterococci are suscep- 
tible in vitro to trovafloxacin. However, this activity is 
much less in vancomvcin-resistant strains [t8] and tro- 
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Table 1 Comparative in vitro activities of trovafloxacin, ciprofloxacin and ofloxacin against gram-positive respiratory pathogens 
Organism No. of MIC9o (mg/1) References 
isolates 
Range Median 
Streptococcus pneumoniae, pen-S 
Trovafloxacin 1867 0.06-0.25 0.12 
Ciprofloxacin 1847 1.0-8.0 2.0 
Ofloxacin 1427 2.0-4.0 4.0 
Streptococcus pneumoniae, pen-R 
Trovafloxacin 498 0.12-0.25 0.12 
Ciprofloxacin 498 1.0-8.0 2.0 
Ofloxacin 343 2.0-4.0 4.0 
Streptococcus pyogenes 
Trovafloxacin 242 0.06-0.5 0.12 
Ciprofloxacin 242 0.5-4.0 0.75 
Ofloxacin 35 1.0-2.0 1.5 
Staphylococcus aureus, MSSA 
Trovafloxacin 666 _< 0.015-0.5 0.06 
Ciprofloxacin 646 0.5-8.0 0.75 
Ofloxacin 194 0.25-0.5 0.5 
Staphylococcus aureus, MRSA, CRSA 
Trovafloxacin 487 1.0-8.0 2.0 
Ciprofloxacin 452 > 4- > 128 > 16 
Ofloxacin 134 2->16 16 
Enterococcus faecalis, van-S 
Trovafloxacin 574 0.25-8 2.0 
Ciprofloxacin 537 1.0-32 2.0 
Ofloxacin 188 2.0-8.0 4.0 
Enterococcus faecalis, van-R 
Trovafloxacin 33 8-16 8 
Ciprofloxacin 19 >4-32 16 
Ofloxacin 12 >8 > 8 
10, 17-33, (S. Kocagoz et al., 35th ICAAC, 
1995, Abstract no. F231) 
9, 17-22, 24-33, (S. Kocagoz et al., 35th ICAAC, 
1995, Abstract no. F231) 
9, 17, 19, 20, 27-29, 33, (S. Kocagoz et al., 
35th ICAAC, 1995, Abstract no. F231) 
8, 17, 21, 28, 33 
9, 17, 21, 28, 33 
17, 28, 33 
9, 18, 20, 24, 25, 30-32, 34, 37 
9, 18, 20, 24, 25, 30-32, 34, 37 
20, 34 
9, 18-20, 22-26, 30, 31, 34-37 
9, 18-20, 22-26, 30, 31, 34-37 
t9, 20, 31, 34, 35 
18-20, 22-26, 30, 32, 34-38 
18-20, 22-26, 30, 32, 34-38 
19, 20, 31, 34, 36 
9, 18-20, 23-26, 30-32, 34, 35, 37, 39 
9, 18-20, 23-26, 30-32, 34, 35, 37, 39 
19, 20, 31, 34, 36 
23, 40, 41, Pfizer data on file 
40, 41 
40 
CRSA, ciprofloxacin-resistant S aphylococcus aureus; MRSA, 
methicillin-resistant S aphylococcus aureus; MSSA, methicillin- 
susceptible Staphylococcus aureus; pen-R, penicillin-resistant 
vafloxacin, in common with other recently developed 
fluoroquinolones uch as sparfloxacin, was unable to 
reduce intracellular viability of vancomycin-resistant 
Enterococcus faecium [39, 40]. 
Gram-Negative Respiratory Pathogens. Overall, trova- 
floxacin is as active in vitro as ciprofloxacin and more 
so than ofloxacin against these pathogens (Table 2). 
Against Haemophilus influenzae, Moraxella catarrhalis 
and Escherichia coli, for example, the median MIC9o 
values for trovafloxacin (0.015, 0.03 and 0.06mg/1, 
respectively) are comparable to those of ciprofloxacin 
and are half those of ofloxacin. The maximum MICs 
recorded for trovafloxacin were 0.12, 0.06 and 33 mg/1. 
Against Pseudomonas aeruginosa, trovafloxacin and 
ciprofloxacin (median MIC90 2 mg/l) are both fourfold 
more potent than ofloxacin. The potency of trovaflox- 
acin exceeds that of ciprofloxacin in the case of Steno- 
trophomonas maltophila. 
Against most of the other gram-negative respiratory 
pathogens tested, trovafloxacin offers an activity gener- 
(MIC _.0.5 nag/I); pen-S, penicillin-susceptible (MIC < 0.5 rag/t); 
van-S, vancomycin-susceptible 
ally between that of ciprofloxacin and ofloxacin. 
Overall, the data indicate that the activity of trovaflox- 
acin is comparable to the activities of ciprofloxacin and 
ofloxacin across a broad spectrum of gram-negative 
pathogens. 
Atypical Respiratory Pathogens. The median MIC9os 
derived from in vitro susceptibility studies indicate that 
trovafloxacin is as active as ofloxacin against Chla- 
mydia pneumoniae and is more active against Legion- 
ella pneumophila nd Mycoplasrna pneumoniae (Table 
3). In vitro studies also show that trovafloxacin is more 
active than ciprofloxacin against Legionella pneumo- 
phila and Mycoplasma pneumoniae. 
Animal Models of Infection 
In an acute systemic infection model, mice were 
infected with one of a range of gram-positive and gram- 
negative organisms administered via intraperitoneal 
injection [45]. Each treatment group of ten mice 
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Table 2 Comparative in vitro activities of trovafloxacin, ciprofloxacin, and ofloxacin against gram-negative r spiratory pathogens 











































403 N0.004-0.05 0.015 9, 18-20~ 22, 26, 3(l-32 
403 ~0.004-0.05 0.015 9, I8-20, 22, 26, 30-32 
67 0.016-0.03 0.023 19, 34 
304 0.008-0.06 0.03 9, I8, 19, 22, 25, 26, 30, 31, 34 
304 0.03-1.0 0.06 16, 18, 19; 22, 25, 26; 30, 31, 34 
53 0.03-0.12 0.075 19, 34 
566 1.0-> t6 2.0 
566 0.5->16 2.0 
357 4.0->16 >8 
9, 19, 20, 24, 25, 30-32, 34, 37, 4! 
9,19,20,24,25,30-32,34,37,4! 
19, 20, 31, 34, 35, 41 
476 <0.015-4.0 0.06 9, 19, 20, 22, 25, 26, 30-32, 3, 37 
476 <0.015-0.5 0.06 9, 19, 20, 22, 25, 26, 30-32, 3, 37 
193 0.05-0.12 0.12 19, 20, 31, 35, 37 
331 0.06-1.0 0.12 16,20, 22, 26, 30-32, 35 
331 0.064.0 0.06 16, 20, 22, 26, 30-32, 35 
95 0.12-2.0 1.0 20, 31, 35 
242 0.05-2.0 1.6 16, 20, 22, 30-32, 34, 35 
242 0.01-4.0 0.31 16, 20, 22, 30-32, 34, 35 
90 0.06-4.0 2.12 20~ 31, 34, 35 
195 0.12-2.0 0.5 16, 20, 22, 25, 26, 30-32, 34, 35 
195 ~0.015-1.0 0.12 16, 20, 22, 25, 26, 30-32, 34, 35 
46 0.12-2.0 0.19 20, 31, 34, 35 
298 0.12-4.0 0.5 16, 20, 22, 25, 26, 30-32, 34, 35 
298 0.03-1.0 0.06 16,20, 22, 25, 26, 30-32, 34, 35 
80 0.06-0.25 0.12 20, 31; 34, 35 
211 0.25 16 2.5 t6, 20, 26, 30-32, 34, 35 
211 0.12->8 1.0 16, 20, 26, 30-32, 34, 35 
100 0.5->8 2.3 20,31,34,35 
227 0.5->8 2.0 20,25,30,31,35,41, 42 
227 1.0-16 >8 20, 25, 30, 31, 35, 41, 42 
197 >8->16 >8 20,25,30,31,35,42 
Table 3 Comparative in vitro activities of trovafloxacin, ciprofloxacin, and ofloxacin against atypica[ respiratory pathogens 




Trovafioxacin 13 1.0 1.0 43 
Ofloxacin 13 1.0 1.0 43 
Legionella pneumophila 
Trovafloxacin 155 <_ 0.004-0.06 0.008 19, 31, 44 
Ciprofloxacin 133 0.015-0.06 0.038 19, 31 
Ofloxacin 155 0.015-0.06 0.032 19, 3l, 44 
Mycoplasma pneumoniae 
Trovafloxacin 50 0.12-0.25 0.185 19, 45 
Ciprofloxacin 10 1.0 1.0 19 
Ofloxacin 50 1.0 1.0 19, 45 
Table 4 In vivo activity of orally-delivered trovafloxacin against gram-positive pathogens inmice [46] 
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Challenge (strain) PDso (95% confidence limits, mg/kg) 
Trovafloxacin Ciprofloxacin Ofioxacin 
Streptococcus pneumoniae (02J0025) 
Streptococcus pneumoniae (Pocidalo 4241) 
Staphylococcus aureus (01A0400), MSSA 
Staphylococcus aureus (0IA0129) 
Staphylococcus aureus (01A1080) 
Staphylococcus aureus (01A1063) 
Streptococcus pyogenes (ATCC12384) 
Enterococcus faecalis (03A0131) 
1.3 (0.6-2.6) >50 >50 
9.7 (5.8-16.1) >50 >50 
2.9 (3.7-11.0) 13.1 (8.2-21.1) NA 
2.0 (1.1-3.6) 1.1 (1.0-3.4) NA 
42.6 (40.8-69.1) >50 >50 
>50 >50 >50 
3.0 (1.7-5.4) 8.7 (4.8-15.5) >50 
6.4 (3.7-11.0) >50 >50 
NA, not available 
received an oral dose of antibiotic administered 0.5 and 
4 h after infection. The numbers of mice that survived 
until day 4 were determined and used to calculate the 
protective dose for 50% of the animals (PDs0). 
Gram-Positive Respirator>" Pathogens. Trovafloxacin 
provided effective treatment in the acute systemic 
infection model [44] and was generally superior to 
ciprofloxacin or ofloxacin (Table 4). The PDs0 values 
indicate that trovafloxacin was particularly effective 
against two strains of Streptococcus pneumoniae, 
whereas both ciprofloxacin and ofloxacin proved inef- 
fective even at the highest dose employed (50 mg/kg/ 
day). 
Against a methicillin-resistant S aphylococcus aureus 
strain (01A0129), trovafloxacin and ciprofloxacin 
appeared to be equally effective. However, data for 
other Staphylococcus aureus strains highlight clear 
differences in potency among the fluoroquinolones. 
Trovafloxacin was more than fourfold more effective 
than ciprofloxacin against a methicillin-susceptible 
strain (01A0400) and was the only fluoroquinolone to 
demonstrate activity against one of the fluoroquino- 
lone-resistant (trovafloxacin MIC=3.12mg/1) strains 
(01A1080). None of the fluoroquinolones exhibited in 
vivo activity against strain 01A1063, which is highly 
resistant to fluoroquinolones (trovafloxacin MIC= 
25 mg/1). 
The pattern of superior activity for trovafloxacin 
extends to the other pathogens investigated. Trovaflox- 
acin was nearly threefold more active than ciproflox- 
acin in protecting mice against Streptococcus pyogenes 
infection and was effective against Enterococcus 
faecalis, against which both ciprofloxacin and ofloxacin 
proved ineffective at the highest dose tested. In these 
tests, the efficacy observed with trovafloxacin generally 
paralleled its in vitro potency against the infecting 
pathogen. 
Two additional animal protection studies have demon- 
strated the relative activities of trovafloxacin, ciproflox- 
acin and ofloxacin in treating infections caused by 
Streptococcus pneumoniae. In one study, two groups of 
ten mice were infected intranasally with Streptococcus 
pneumoniae strain Pocidalo 4241 [47]. Oral twice-daily 
therapy with trovafloxacin or ciprofloxacin was 
initiated 18 h after infection and maintained for 3 days. 
Survivors were monitored over 10 days, after which the 
PDso was calculated. The results suggest that trovaflox- 
acin is more potent in vivo than ciprofloxacin. Trova- 
floxacin protected 90-100% of the animals with oral 
therapies of 12.5-50 mg/kg, giving a PDso of 2.1 mg/kg. 
In contrast, ciprofloxacin protected only 20-30% of 
challenged animals at doses of 75-100 mg/kg. 
A second study employed a similar mouse pneumonia 
model to compare the activities of trovafloxacin, cipro- 
floxacin and ofloxacin against one penicillin-susceptible 
Streptococcus pneumoniae strain (Pocidalo 4241) in 
immunocompetent mice and three penicillin-resistant 
isolates in leucopenic mice [48]. Therapy began 6 h and 
3 h, respectively, after infection and involved the 
administration of two subcutaneous doses per day for 3 
days. Untreated, control mice died by day 3 post-chal- 
lenge in this model. Survival rates with trovafloxacin 
were significantly greater than with ciprofloxacin or 
ofloxacin. A once-daily 25 mg/kg dose of trovafloxacin 
protected 91% of the mice infected with the penicillin- 
susceptible strain 4241 and 66-100% of mice infected 
with penicillin-resistant s rains. By comparison, in the 
case of ciprofloxacin, the next most effective agent, a 
dose of 100mg/kg protected only 23% and 58% of 
mice, respectively. 
An indication of the greater clinical potential of trova- 
floxacin against Streptococcus pneumoniae is also 
provided by its superior distribution into the lung 
tissues compared with ciprofloxacin. Girard et al. [46] 
found that, in mice infected with strain 4241, the 
maximum concentration of trovafloxacin in lung tissue 
was at least twice that of ciprofloxacin, and that the 
half-life of trovafloxacin was over threefold greater. 
Consequently, the area under the lung concentra- 
tion-time curve for trovafloxacin was nearly sixfold 
greater than for ciprofloxacin. 
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Table 5 In vivo activity of orally-delivered trovafloxacin against gram-negative pathogens in mice [46] 
Challenge (strain) PDs~ (95% confidence limits, mg/kg) 
Trovafloxacin Ciprofloxacin Ofloxacin 
Enterobacter cloacae (67B0153) 
Escherichia coli (51A0266) 
Klebsiella pneumoniae (ATCC 43816) 
Morganella morganii (97A0096) 
Pseudomonas eruginosa (52A0266) 
Proteus mirabilis (57C0175) 
12.5 (6.7-23.1) 18.1 (7.6-42.8) NA 
2.3 (0.8-6.1) <0.8 <0.8 
1.1 (0.4-1.8) 2.5 (1.8-3.3) NA 
16.8 (7.6-37.3) 4.6 (2.3-9.2) NA 
6.5 (3.5-12.0) 1.2 (0.5-2:6) 1.9 (018-4.7) 
5.6 (3.0-10.3) 6.9 (3.8-12.9) 17.5 (7.7-39.8) 
NA, not available 
Gram-Negative Respiratory Pathogens. The acute 
systemic infection model that established superior 
potency of trovafloxacin against gram-positive respira- 
tory pathogens has also shown that trovafloxacin, cipro- 
floxacin and ofloxacin offer broadly comparable in vivo 
activities against important gram-negative respiratory 
pathogens [46]. Trovafloxacin was slightly more active 
against Enterobacter cloacae and Klebsiella pneurnoniae 
than ciprofloxacin, but slightly less so than ciproflox- 
acin and ofloxacin against Escherichia coli and Pseudo- 
monas aeruginosa, and markedly less effective than 
ciprofloxacin against Morganella morganii (Table 5). 
The activity of trovafloxacin against Proteus rnirabilis 
was slightly higher than that of ciprofloxacin and 
markedly higher than that of ofloxacin. 
Atypical Respiratory Pathogens. The in vivo activity of 
trovafloxacin against Legionella pneumophila has been 
explored and compared with that of ofloxacin in an 
animal model featuring lethal lung infections with this 
atypical pathogen [44]. Guinea pigs infected intratra- 
cheally with Legionella pneumophila serogroup 1 strain 
F889 received a single dose of trovafloxacin (7.5 rag/ 
kg), ofloxacin (10 mg/kg) or saline, administered intra- 
peritoneally once daily for 5 days. 
All guinea pigs treated with trovafloxacin or ofloxacin 
survived 14 days after infection, whereas none of the 
control guinea pigs survived more than 5 days. No 
significant differences in lung histology were noted 
between the trovafloxacin- and ofloxacin-treated 
animals who survived. Only two of the seven lung 
samples from the trovafloxacin treatment group were 
positive for Legionella pneumophila, compared with 
three of the seven lung samples from the ofloxacin 
group. The major difference observed between the 
treatment groups was slower weight gain in the trova- 
floxacin group, which could have been attributable to 
lower initial weights in this group before infection 
[44]. 
A similar study involving the same experimental model 
has shown that trovafloxacin (5 mg/kg/day) completely 
eradicated Legionella pneumophila from the lungs and 
spleen in all animals after 4-5 days of treatment and 
that Legionella could not be recovered after 28 days (E. 
Millas et al., 36th ICAAC, 1996, Abstract no. E76). 
The in vitro susceptibility data, combined with better in 
vivo activity than either ciprofloxacin or ofloxacin, led 
Edelstein et al. [44] to conclude that trovafloxacin is 
one of the most active antimicrobial agents tested 
against Legionella species, being more effective than 
ciprofloxacin and other antibiotics such as azithro- 
mycin, erythomycin, clavulanic acid and tazobactam. 
Tissue and Intracellular Penetration of 
Trovafloxacin 
Positron emission tomography performed in healthy 
volunteers revealed that the peak concentration of 
trovafloxacin in lung following a 200 mg dose was 
22.5 +7.1 pog/g [A.J. Fischman et al. 37th ICAAC, 1997, 
Abstract no. A68]. Edelstein et al. [44] showed that the 
maximum concentration of trovafloxacin in guinea pig 
alveolar macrophages in vitro was 28-fold greater than 
the concentration i extracellular fluid. Concentration 
in serum, alveolar macrophages, epithelial ining and 
bronchial mucosa of 1.01mg/kg, 0.37, 10.23 and 
0.93 mg/1, respectively, have been recorded 24 h after a 
single oral dose of 200 mg trovafloxacin i humans [47]. 
These concentrations exceeded even the highest 
median MIC90 values of respiratory pathogens 
presented in Tables 1-3, and should be sufficiently high 
to ensure bacterial eradication. 
Conclusions 
Fluoroquinolones comprise just one of many classes of 
antimicrobial agents used to treat the gamut of commu- 
nity- and hospital-acquired respiratory tract infections 
in humans. Although ciprofloxacin and ofloxacin find 
some use in the treatment of acute exacerbations of 
chronic bronchitis and in combination with other 
agents, for hospital-acquired pneumonia, their more 
widespread use for community-acquired pneumonia is 
limited by their relatively poor activity against pneumo- 
cocci and atypical pathogens. Further, the use of pres- 
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ently marketed f luoroquinolones has been accompa- 
nied by the emergence of f luoroquinolone-resistant 
Staphylococcus aureus and Streptococcus pneumoniae 
strains. Therefore,  a demand exists for new antibiotics 
with broad-spectrum activities that enable them to be 
prescribed with confidence for empiric monotherapy.  
The resuks of in vitro and in vivo studies indicate that 
trovafloxacin offers activity comparable to that of 
ciprofloxacin and ofloxacin against gram-negative 
respiratory pathogens together with superior activity 
against gram-posit ive organisms. Trovafloxacin is also 
active against the atypical respiratory pathogens. Its 
extensive activity against pathogens commonly  impli- 
cated in respiratory infections, together with its ability 
to achieve concentrations in respiratory tissue far in 
excess of MICs, suggests that trovafloxacin may 
provide effective empiric t reatment of community-  and 
hospital-acquired infections, including sinusitis, acute 
exacerbations of chronic bronchitis, community-  and 
hospital-acquired pneumonia,  and atypical pneu- 
monia. 
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